Pasithea Therapeutics Corp. (KTTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KTTA Stock Price Chart Interactive Chart >
KTTA Price/Volume Stats
| Current price | $0.84 | 52-week high | $8.50 |
| Prev. close | $0.83 | 52-week low | $0.81 |
| Day low | $0.82 | Volume | 55,800 |
| Day high | $0.85 | Avg. volume | 543,312 |
| 50-day MA | $1.14 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 19.45M |
Pasithea Therapeutics Corp. (KTTA) Company Bio
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.
Latest KTTA News From Around the Web
Below are the latest news stories about Pasithea Therapeutics Corp that investors may wish to consider to help them evaluate KTTA as an investment opportunity.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimulation (“rTMS”) -- MIAMI BEACH, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments |
Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel WeinbergerNewest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illnessMIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the appointment of Dr. Daniel Weinberger to its Scientific Advisory Board (“SAB”). Dr. Weinberger is |
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisCompany commences program to develop a tolerizing vaccine and names Hooke Laboratories as its research partnerMIAMI BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced a new chemical entity (“NCE”) development program and named Massachusetts-based Hooke Laboratories as its res |
Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine TreatmentsIn-person clinic will provide ketamine therapy and other novel mental health treatments, including repeated transcranial magnetic stimulation (“rTMS”)MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, will open a |
Casino Stocks: Why LVS, MLCO and WYNN Are Getting Buy-In TodayCasino stocks are on the move today thanks to a recent report out of China's Macau concerning new government regulations. |
KTTA Price Returns
| 1-mo | -27.59% |
| 3-mo | -17.65% |
| 6-mo | -80.24% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.54% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...